ASRS 2023: Megan Baldwin, CEO of Opthea Limited, shares updates on sozinibercept

News
Video

Megan Baldwin, PhD, CEO and managing director of Opthea Limited, spoke with our team about the company's clinical trial drug OPT-302 (sozinibercept) at the 2023 ASRS annual meeting.

Megan Baldwin, PhD, CEO and managing director of Opthea Limited, spoke with our team about the company's clinical trial drug OPT-302 (sozinibercept) at ASRS 2023.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Megan Baldwin, PhD:

Hello, I'm Megan Baldwin. I'm CEO and managing director of Opthea Limited. Opthea Limited is here at the ASRS, in Seattle. We will have a presentation by Dr Dante Pierramici on Monday of this week at ASRS. He'll be talking about OPT-302, which is also just announced to be called sozinibercept. Though he'll be talking about the pharmacokinetic and safety data that we've demonstrated with the molecule to date. We are currently in phase 3 clinical development, recruiting patients globally for our product, which is in development in combination with both Eylea, or aflibercept, as well as Lucentis ranibizumab. And the objective of our approach is to provide additional clinical benefit visual acuity improved outcomes for patients on top of standard of care.

It will mean that ophthalmologist physicians worldwide have an additional therapeutic option for patients in order to improve their clinical outcomes, which I think is the number one unmet medical need for patients right now. Right now, there's very limited treatment options. We understand that the VEGF-A inhibitors are a very clinically, you know, commercially successful class of drugs. But the fact is that many, many patients actually don't respond optimally, and that there's additional opportunity to provide visual acuity benefit across the board for many, many patients worldwide. And that's what we want to do with sozinibercept, OPT-302, which is a molecule that achieves a broader blockade of the validated pathways in the disease.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.